Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001
NIH and Matinas BioPharma Announce Research Collaboration to Identify Novel HIV Therapy Utilizing LNC Platform Delivery Technology
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor